Work

VERU-111, an novel oral α and β tubulin inhibitor, has potent activity against paclitaxel sensitive and resistant prostate cancer

Year: 2018

Type: conference-abstract

Source: European Urology Supplements

DOI: 10.1016/s1569-9056(18)31195-3

Authors: R. Getzenberg, J. Dalton, D. Miller, M. Steiner

Language: English

Topic: Prostate Cancer Treatment and Research

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2793541759

Cites:

Cited by:

Related to: 10